Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00635024 · OUTCOME

Overall Survival (OS)

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2017-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to 2 years

What was measured

OS was defined as the time from registration to death of any cause.

Groups in this outcome

Anti-thymocyte Globulin/Melphalan

Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Anti-thymocyte Globulin/Melphalan1

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Anti-thymocyte Globulin/Melphalan2.9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2.9
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
OS was defined as the time from registration to death of any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)
    id
    OG000
    title
    Anti-thymocyte Globulin/Melphalan
param Type
MEDIAN
reporting Status
POSTED
time Frame
up to 2 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice